載入中
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
前收盤價
US$6.34
+US$0.13 · +2.09%
盤中時間採用ET。市場資料可能有所延遲。
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
日內區間
目前US$6.34
52週區間
目前US$6.34
盤中時間採用ET。市場資料可能有所延遲。
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
日內區間
目前US$6.34
52週區間
目前US$6.34
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 |
|---|---|---|---|---|
| 營收 | 899.5萬 USD | — | — | — |
| 毛利 | 899.5萬 USD | — | — | — |
| 研究與開發 | 7396.6萬 USD | 5903.6萬 USD | 3388.6萬 USD | 3052.2萬 USD |
| 銷售、一般及管理費用 | 2780.9萬 USD | 1915.8萬 USD | 1451.4萬 USD | 944.7萬 USD |
| 營業費用 | 1.02億 USD | 7819.4萬 USD | 4840萬 USD | 3996.9萬 USD |
| 利息收入 | 1308.6萬 USD | 962.9萬 USD | 243.1萬 USD | 46.5萬 USD |
| 利息支出 | 69.7萬 USD | 236.7萬 USD | 779.4萬 USD | 24.1萬 USD |
| 折舊和攤銷 | 21.3萬 USD | 16.7萬 USD | 16.2萬 USD | 12.9萬 USD |
| 營業利益 | −9278萬 USD | −7819.4萬 USD | −4840萬 USD | −3996.9萬 USD |
| 淨利 | −8060.5萬 USD | −7110.9萬 USD | −6385.4萬 USD | −3972.2萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$23.50
上漲空間 270.66%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1083.56萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM528.1萬0.01%787.4億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF353.43萬0.00%954億 USD0.05%US$235+0.80%
Vanguard U.S. Momentum Factor ETFVFMO313.18萬0.16%19億 USD0.13%US$230.11+1.02%
State Street SPDR S&P Pharmaceuticals ETFXPH286.93萬0.62%4.62億 USD0.35%US$64.65+1.60%
Vanguard Russell 2000 ETFVTWO192.27萬0.01%180億 USD0.06%US$112.66+0.50%
iShares Biotechnology ETFIBB152.21萬0.01%108.2億 USD0.44%US$206.49+3.00%
Dimensional - US Small Cap ETFDFAS136.51萬0.00%338.69億 USD0.31%US$78.35+0.32%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard U.S. Momentum Factor ETFVFMOState Street SPDR S&P Pharmaceuticals ETFXPHVanguard Russell 2000 ETFVTWOiShares Biotechnology ETFIBBDimensional - US Small Cap ETFDFASAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
